Compare with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GLENMARK PHARMA ALKEM LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x - 10.2 - View Chart
P/BV x 6.7 1.5 458.0% View Chart
Dividend Yield % 0.6 0.7 94.0%  

Financials

 ALKEM LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
GLENMARK PHARMA
Mar-19
ALKEM LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589712 223.3%   
Low Rs1,232484 254.8%   
Sales per share (Unadj.) Rs417.5349.6 119.4%  
Earnings per share (Unadj.) Rs56.332.8 171.7%  
Cash flow per share (Unadj.) Rs64.744.3 146.0%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.3 269.0%  
Book value per share (Unadj.) Rs292.9198.6 147.5%  
Shares outstanding (eoy) m119.57282.17 42.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.7 197.7%   
Avg P/E ratio x25.118.2 137.4%  
P/CF ratio (eoy) x21.813.5 161.7%  
Price / Book Value ratio x4.83.0 160.1%  
Dividend payout %22.66.1 369.8%   
Avg Mkt Cap Rs m168,653168,625 100.0%   
No. of employees `000NA12.0 0.0%   
Total wages/salary Rs m9,17120,561 44.6%   
Avg. sales/employee Rs ThNM8,196.0-  
Avg. wages/employee Rs ThNM1,708.1-  
Avg. net profit/employee Rs ThNM768.5-  
INCOME DATA
Net Sales Rs m49,91598,655 50.6%  
Other income Rs m1,6452,081 79.0%   
Total revenues Rs m51,561100,736 51.2%   
Gross profit Rs m8,48215,858 53.5%  
Depreciation Rs m1,0063,259 30.9%   
Interest Rs m6713,346 20.0%   
Profit before tax Rs m8,45111,335 74.6%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m1,6063,756 42.8%   
Profit after tax Rs m6,7319,250 72.8%  
Gross profit margin %17.016.1 105.7%  
Effective tax rate %19.033.1 57.3%   
Net profit margin %13.59.4 143.8%  
BALANCE SHEET DATA
Current assets Rs m27,06266,968 40.4%   
Current liabilities Rs m15,32440,211 38.1%   
Net working cap to sales %23.527.1 86.7%  
Current ratio x1.81.7 106.0%  
Inventory Days Days6783 79.8%  
Debtors Days Days4181 50.8%  
Net fixed assets Rs m12,61033,322 37.8%   
Share capital Rs m239282 84.7%   
"Free" reserves Rs m34,49055,770 61.8%   
Net worth Rs m35,02756,052 62.5%   
Long term debt Rs m1,21235,738 3.4%   
Total assets Rs m54,387132,888 40.9%  
Interest coverage x13.64.4 310.0%   
Debt to equity ratio x00.6 5.4%  
Sales to assets ratio x0.90.7 123.6%   
Return on assets %13.69.5 143.6%  
Return on equity %19.216.5 116.5%  
Return on capital %24.917.8 139.5%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56362,998 10.4%   
Fx outflow Rs m3,01222,859 13.2%   
Net fx Rs m3,55240,140 8.8%   
CASH FLOW
From Operations Rs m7,25913,242 54.8%  
From Investments Rs m1,864-6,990 -26.7%  
From Financial Activity Rs m-9,273-7,387 125.5%  
Net Cashflow Rs m-150-2,971 5.0%  

Share Holding

Indian Promoters % 66.9 48.3 138.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 6.9 479.7%  
FIIs % 0.0 34.4 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 56,727 120.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

7 Stocks That Will Generate Alpha over the Next Decade(Profit Hunter)

Oct 29, 2019

Here's your chance benefit from a safe approach to making money in stock markets .

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Nov 11, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS